Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.

@article{Snchez1998ClinicalOI,
  title={Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.},
  author={Evelia S{\'a}nchez and Ignacio Chac{\'o}n and M Moreiras Plaza and Eva Erice Mu{\~n}oz and Miguel {\'A}ngel Cruz and Betzaida Martinez and Laura L{\'o}pez and Juan Carlos Mart{\'i}nez-Montero and Juan Luis Orradre and Ana Isabel Gonz{\'a}lez S{\'a}ez and Juan Fernando V{\'e}lez Garc{\'i}a and Miguel {\'A}ngel Piris},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 5},
  pages={1931-9}
}
PURPOSE The goal of this work was to perform a comprehensive exploration of the relationship between the clinical outcome of diffuse large B-cell lymphoma (DLBCL) and the expression of a panel of tumor suppressor and oncogenic proteins, which includes some cell-cycle regulator proteins involved in the p53 pathway. PATIENTS AND METHODS To this end, we collected the clinical data of 141 patients with DLBCL and immunohistochemically analyzed diagnostic tumoral tissue from each patient for the… CONTINUE READING